Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liposomal mitoxantrone for relapsed or refractory peripheral T-cell lymphoma (real-world, ambispective cohort)
ChiCTR2200062067Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Oncology, Harbin First Hospital
- Start
- Aug 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of mitoxantrone hydrochloride liposome in peripheral T-cell lymphoma (PTCL), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL) and 1 more, sponsored by Institute of Hematology and Oncology, Harbin First Hospital. Primary endpoint: Objective response rate. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
mitoxantrone hydrochloride liposome
03
Conditions
peripheral T-cell lymphoma (PTCL)angioimmunoblastic T-cell lymphoma (AITL)anaplastic large cell lymphoma (ALCL)natural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on ChiCTR2200062067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200062067.